Adm1n: Created page with "'''A-836,339''' is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB2, with Ki values of 0.64nM at CB..."

2015-02-15T11:11:55Z

Created page with "'''A-836,339''' is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB2, with Ki values of 0.64nM at CB..."

New page

'''A-836,339''' is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for [[CB2]], with Ki values of 0.64nM at CB2 vs 270nM at the psychoactive [[CB1]] receptor, but while it exhibits selective analgesic, anti-inflammatory and anti-hyperalgesic effects at low doses, its high efficacy at both targets results in typical [[cannabis]]-like effects appearing at higher doses, despite its low binding affinity for CB1. In 2012 A-836,339 was detected via X-ray crystallography in a "dubious product" sold in Japan, though the product was described as a white powder, not herbal incense, it was suggested to be for human consumption.

A-836,339 - Revision history

Adm1n: Created page with "'''A-836,339''' is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB2, with Ki values of 0.64nM at CB..."